Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.54 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.53 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.47 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.47 |
| ▸ | PLG | P00747 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | NOXO1 | Q8NFA2 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | LY6K | Q17RY6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20520038 | 0.97 | CSNK2A2 (0.51) | CSNK2A2CSNK2BCSNK2A1CAMK2BPRSS1 | |
| SCHEMBL20520180 | 0.97 | PRSS1 (0.55) | CSNK2A2CSNK2BCSNK2A1CAMK2BPRSS1 | |
| SCHEMBL20520124 | 0.96 | CSNK2A2 (0.54) | CSNK2A2CSNK2BCSNK2A1CAMK2BPRSS1 | |
| SCHEMBL20519818 | 0.94 | FOLH1 (0.53) | CSNK2A2CSNK2BCSNK2A1CAMK2BPRSS1 | |
| SCHEMBL18736360 | 0.91 | TDP1 (0.48) | CSNK2A2CSNK2BCSNK2A1CAMK2BPRSS1 | |
| SCHEMBL18705344 | 0.91 | CSNK2A2 (0.57) | CSNK2A2CSNK2BCSNK2A1CAMK2BPRSS1 | |
| SCHEMBL18705384 | 0.90 | PRSS1 (0.48) | CSNK2A2CSNK2BCSNK2A1CAMK2BPRSS1 | |
| SCHEMBL18705379 | 0.89 | CSNK2A2 (0.48) | CSNK2A2CSNK2BCSNK2A1CAMK2BPRSS1 | |
| SCHEMBL18736359 | 0.87 | ADORA2A (0.52) | CSNK2A2CSNK2BCSNK2A1CAMK2BPRSS1 | |
| SCHEMBL20519968 | 0.87 | FOLH1 (0.60) | CSNK2A2CSNK2BCSNK2A1CAMK2BPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2021-12-02 | — | — | US | disclosed |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2021-03-23 | — | — | US | disclosed |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTUARI THERAPEUTICS LIMITED (GB/GB) (GB) | 2018-10-04 | — | — | US | disclosed |
| WO-2017060729-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CENTAURI THERAPEUTICS LIMITED (GB) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369850-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | CSNK2A2 3598/4885CSNK2B 3959/4885CSNK2A1 3689/4885 |
| US-10953100-B2 | Compounds and therapeutic uses thereof | CD47, MYD88, NFATC1 | CSNK2A2 3598/4885CSNK2B 3959/4885CSNK2A1 3689/4885 |
| US-20180280521-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | CD47, MYD88, NFATC1 | CSNK2A2 3598/4885CSNK2B 3959/4885CSNK2A1 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.